As soon as vaccine companies announced they were developing a COVID-19 vaccine, doctors, scientists, researchers and other experts raised warnings1,2 about the problematic history of coronavirus vaccines and their propensity to produce antibody-dependent enhancement (ADE), which could make vaccinated individuals more susceptible to infection by SARS-CoV-2 or its variants. It is also called paradoxical immune enhancement (PIE), which I believe is a more accurate description of what is happening. Among those issuing early warnings were Robert F. Kennedy Jr., who in my interview with him — featured in “Well-Known Hazards of Coronavirus Vaccines” — recounted previous failed coronavirus vaccine trials in which he said the vaccinated animals died when exposed to the wild virus. Considering all previous coronavirus vaccine efforts have failed for this reason, it seemed reasonable to suspect that a COVID-19 vaccine might have similar problems, and that such effects might remain hidden for some time since animal testing was bypassed. Recent research suggests such fears might still be warranted, although conclusive evidence that ADE is in fact occurring has not been produced. Trial Subjects Have Not Been Informed of ADE RiskThe October 28, 2020, paper,3 “Informed Consent Disclosure to Vaccine Trial Subjects of Risk of COVID-19 Vaccine Worsening Clinical Disease,” stressed that “COVID-19 vaccines designed to elicit neutralizing antibodies may sensitize vaccine recipients to more severe disease than if they were not vaccinated,” and criticized vaccine makers for not clearly informing participants in current vaccine trials of this risk.
What Is ADE?What exactly is ADE, and what does it mean? In a nutshell, it means that rather than enhance your immunity against the infection, the vaccine actually enhances the virus’ ability to enter and infect your cells, resulting in more severe disease than had you not been vaccinated.5 Needless to say, this is the exact opposite of what a vaccine is supposed to do. The 2003 review paper “Antibody-Dependent Enhancement of Virus Infection and Disease” explains it this way:6
Vaccinated People More Susceptible to South African VariantAs feared from the beginning, vaccinated individuals do appear to be more susceptible to infection by certain variants of SARS-CoV-2, although it remains to be seen whether they are more prone to serious illness. A study by researchers at Tel Aviv University and Clalit Health Services in Israel found the South African variant of SARS-CoV-2, dubbed B.1. 351 — which presently accounts for about 1% of COVID-19 cases in Israel — affects people vaccinated with Pfizer’s mRNA vaccine to a greater extent than unvaccinated people.7,8,9,10 The researchers compared 400 individuals who had tested positive for the B.1.351 variant two weeks or more after receiving at least one dose of Pfizer’s COVID-19 vaccine against 400 unvaccinated individuals who had been infected. Among the 150 people who were fully vaccinated, having received both shots of the vaccine, the variant was eight times more prevalent than in unvaccinated individuals (5.4% compared to 0.7%). An estimated 53% of Israel’s 9.3 million inhabitants have received the Pfizer vaccine.11 While Moderna’s vaccine is also available in Israel, it was not included in this investigation. According to professor Adi Stern, Ph.D.,12 at Tel Aviv University, who said the findings took her by surprise:13
For clarity, while the risk of infection appears significantly greater, it is still unknown whether the variant might generate more serious illness in vaccinated individuals. The study did not report disease outcomes, stating it would be “statistically meaningless” to do so since the number of vaccinees infected was too low. That said, professor Ran Balicer, director of research at Clalit Health Services, which provided assistance for the study, noted this is the first study “to be based on real-world data, showing that the vaccine is less effective against the South Africa variant, compared to both the original virus and the British variant.”14 Other Research Suggests B.1.351 May Evade First-Gen VaccinesAnother recent study,15 reported by Times of Israel,16 was done by researchers at Ben-Gurion University of the Negev. Here, they analyzed blood samples to assess vaccine response to the South African variant. As reported by Times of Israel:17
The study18 found that while the Pfizer vaccine produced high levels of neutralizing antibodies against the generic strain of SARS-CoV-2 and the British variant, it fared worse against the South African variant. Overall, the neutralization potency of the Pfizer vaccine was 6.8 times lower for the B.1.351 variant compared to the generic strains. It was also less effective against strains that have attributes of both the British and the South African variants. According to the authors:19
As you’d expect, vaccine makers are already hard at work tweaking their formulas to target various mutations of the virus, so don’t be surprised if all of a sudden vaccinated individuals start getting called back for additional shots. As reported by STAT News:22
Pfizer Study Reports Drop in Effectiveness Against B.1.351Last but not least, Pfizer’s own investigation, published in The New England Journal of Medicine23 March 8, 2021, found its vaccine was about two-thirds less effective, in terms of neutralizing potency, against the South African variant, B.1.351, compared to other forms of the virus.
What STAT News does not mention is that the vaccines may also generate nonneutralizing (aka binding) antibodies25 which, instead of preventing infection, can trigger ADE, a paradoxical immune enhancement that increases your susceptibility to infection and more severe illness. Aside from the studies already mentioned at the beginning of this article, many others have raised concerns about coronavirus vaccines and ADE in particular. Among them is the May 2020 mini review26 “Impact of Immune Enhancement on COVID-19 Polyclonal Hyperimmune Globulin Therapy and Vaccine Development.” As in many other papers, the authors point out that:27
Th2 Immunopathology Is Another Potential RiskAnother potential risk is that of Th2 immunopathology, especially among the elderly. As reported in a PNAS news feature:28
Full Extent of Risks Remain To Be SeenWhether or not COVID-19 vaccines can trigger ADE or Th2 immunopathology remains to be seen. As or right now, studies suggest vaccinated individuals are at increased risk of contracting lab-confirmed infection with variants such as the South African B.1.351 strain, but there’s no telling whether they actually get sicker than unvaccinated individuals. Similarly, while there are now hundreds of cases of fully vaccinated individuals having being diagnosed with COVID-19, some of whom have died as a result,29 it’s too early to tell whether ADE is at play. We’re currently moving into summer in the Western hemisphere, a time when respiratory viruses tend to be less prevalent in general, so I suspect the real test will come this fall and winter. So, while some argue that ADE is a “non-issue” with COVID-19 vaccines simply because we haven’t seen any signs of it yet,30 even with new variants, I have my doubts. I suspect we might still see it once flu season sets in. Besides, ADE is far from the only potential problem. There are many other potential side effects, some of which may take months or years to develop, while others may be lethal within days or even hours. The vaccines may also be problematic for already immunosuppressed patients. The reason for this is because they don’t develop a robust neutralizing antibody response from the vaccines, and there’s research31 warning that developing a poor neutralizing antibody response after an initial exposure to certain coronaviruses might result in more severe illness upon re-exposure. Might the same apply if you fail to develop robust neutralizing antibodies in response to mRNA gene therapy? A recent JAMA study32,33 found only 17% of organ transplant recipients mounted detectable antibodies after their first dose of Pfizer or Moderna mRNA vaccine. Among patients taking antimetabolites, only 8.75% had detectable antibodies against SARS-CoV-2 following vaccination. As noted by the authors:
In my view, there are still so many potential avenues of harm and so many uncertainties, I would encourage everyone to do your homework, keep reading and learning, weigh the potential pros and cons, and take your time when deciding whether to get any of these COVID-19 gene therapies. from https://ift.tt/2OYAVJi Check out https://drpandatv.weebly.com/
2 Comments
Ray gouthro
9/4/2021 05:00:21 am
I follow everything and I do believe we need to balance the scale on fact not fake news as trump explains and he was right on that statement.masteroverdisaster will be a voice with no opion just fact. So honoured you send me facts.conclusion.we are hit with a corona tsunami and my advice is get your pro ,surf board and ride this wave with me and we can clean up the mess together at the end.
Reply
Meagan
9/10/2021 08:08:57 pm
Hello,
Reply
Leave a Reply. |